NCT02257359View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 18, 2014

Primary Completion Date

January 29, 2015

Study Completion Date

January 29, 2015

Conditions
Embryo Transfer
Interventions
DRUG

Epelsiban

Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.

Trial Locations (1)

66211

GSK Investigational Site, Overland Park

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY